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1. Introduction  
In the dialysis clinic, water is an essential vehicle to deliver life-saving treatment to patients 
suffering from varying degrees of kidney failure, both acute and chronic. Clean water is 
vital, as the key ingredient used to prepare hemodialysis fluid (dialysate solution), and on-
line generation of substitution fluid for hemodiafiltration. Generally all fluids used to treat 
patients suffering from kidney failure may come into contact with the blood of the patient, 
whether directly or indirectly (across a membrane), and theoretically could transport 
contaminants resulting in a negative impact on patient health. Of the microbiological 
contaminants found in water, endotoxin is given considerable attention, given its difficulty 
for removal and inactivation from water and water distribution systems (Smeets et al., 2003; 
Perez-Garcia & Rodriguez-Benitez, 2000) and its inherent pyrogenicity (G. Lonnemann, 
2000). 
Endotoxins are found in all gram-negative bacteria, although slight differences in chemical 
structure are found between varying bacterial strains. The term endotoxin is typically used 
to describe a complex of protein and lipopolysaccharide (LPS) molecules found in the outer 
cell wall of gram-negative bacteria, that either slough off during growth, or are released 
upon cell lysis. Endotoxin and lipopolysaccharide are typically used interchangeably in 
literature, although in clinical discussion the term endotoxin is most often used, as it is the 
metric used to monitor water and dialysis fluid quality. Lipopolysaccharide is a vital 
component of the outer membrane of gram-negative bacteria, providing numerous 
physiological functions and comprising nearly 75% of the bacterium outer surface area 
(Raetz, 1991). Lipopolysaccharides consist of three components: a long heteropolysaccharide 
chain (O-specific chain) which represents a surface antigen; a core oligosaccharide; and a 
lipid component termed lipid A used as an anchor in the outer cell membrane (Rietschel et 
al., 1994; Gorbet & Sefton, 2005). Molecular weights of most lipopolysaccharides are 10 – 20 
kDa; however, due to their amphiphilic nature, LPS molecules can form aggregates (100 – 
1000 kDa) which are too large to pass through dialysis membranes. It has been shown that 
components of lipopolysaccharide (lipid A) are able to pass through dialysis membranes, 
can elicit a pyrogenic response (Naveh-Many et al., 1999), and contribute to long-term 
morbidity and inflammation (H. Schiffl, 2000; Raj et al., 2009).  
Lipid A is the most conserved component of lipopolysaccharide throughout all gram-
negative bacteria, and as such is responsible for the majority of the pyrogenic activity. Lipid 
A consists of a phosphorylated N-acetylglucosamine (NAG) dimmer connected to saturated 
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fatty acid chains; variability within the composition of the fatty acids will determine the 
toxic property of lipid A, as well as play a role in resistance to host antimicrobial factors and 
avoiding recognition from specific components of the host immune system (Bland et al., 
1994; Gunn, 2001; Qureshi et al., 1999). The O-specific side chain component of LPS is 
responsible for complement activation and contributes to fever and hypotension, as well as 
binding to endotoxin recognition molecules within the body (Valvano, 1992; Bailat et al., 
1997). Once within the body, LPS tend to be found at higher concentrations within the 
spleen and liver (uptake by phagocytosis) where they are cleared from the body (Haeffner-
Cavaillon et al., 1998).            
Dialysis patients are typically exposed to 90 – 120 liters of dialysis fluid per treatment, which 
equates to an annual exposure of 20 – 30,000 liters (Weber et al., 2004; I. Ledebo, 2002). With 
constant exposure to large amounts of fluid, the opportunity for a dialysis patient to 
experience an inflammatory or pyrogenic reaction due to contamination within the dialysis 
fluid is increased. For hemodialysis, fluids that are used for treatments do not have to be 
sterile; however, the lower the microbial concentration, the lower the risk of patient reaction. 
Because of this risk, regional regulatory boards have implemented limits to the total 
microbial count that can be present in fluids that are to be used in dialysis treatments. 
However, even if water treatment systems are in place, contamination is still a possibility 
and a risk. Dialysis fluid used for clinical treatments may become contaminated from either 
the source water, the dialysate concentrate, or from the water distribution system. Due to 
the ubiquitous nature of biofilm, and its propensity to generate endotoxin, this problem 
affects not only hemodialysis, but all extracorporeal therapies (Kanagasundaram et al., 
2009).     
Regardless of the treatment processes used to create water for dialysis fluid, the final 
opportunity to remove microbial contaminants from the fluid path prior to patient exposure 
is the dialysis membrane contained within the dialyzer. Dialysis fluid comes into direct 
contact with this membrane, and due to transmembrane pressure differences and the 
permeability of the filter, especially for high-flux dialyzers, the potential for dialysis fluid to 
enter the blood compartment and return to the patient is significant (N. Hoenich, 2007). It is 
this final barrier, the dialyzer membrane, where the last opportunity resides to remove 
endotoxins from solution (Weber et al., 2009), by means of membrane manipulation. The 
aim of the following research is to achieve a more thorough understanding of how 
endotoxin interacts with various physical characteristics of the dialysis membrane, and how 
to exploit these interactions to increase endotoxin removal from dialysis fluid. 
2. Membrane manipulation for endotoxin removal 
The degree of contaminated dialysis fluid including bacteria, bacterial fragments and 
endotoxin that may enter the bloodstream of a patient during treatment depends largely 
upon the porosity and other physical characteristics of the membrane being utilized. Back-
filtration is based upon geometrical and permeability properties of the hollow fiber 
membrane, and cannot be avoided in high-flux hemodialysis (Ofsthun & Leypoldt, 1995). 
However, both physical and chemical means can be used to prohibit endotoxin from 
crossing the membrane, by removing it from solution and holding it within the dialyzer 
membrane. Numerous studies have been performed to determine the properties of 
hemodialysis membranes that best manipulate the transfer of endotoxin, by removing it 
from the dialysis circuit (Canaud et al., 2000; Lonnemann et al., 2001). Surface treatments, 
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polymer modifications, as well as chemical changes to the membrane composition, have 
been investigated to ascertain their influence on preventing or minimizing endotoxin and 
bacterial fragment flux across the membrane. Some studies have shown that even the choice 
of sterilization modality may have an impact on the membrane, and affect the ability to 
retain endotoxin (Gomila et al, 2006; Krieter et al., 2008). It is necessary to understand how a 
particular dialysis membrane interacts with endotoxin and other dialysis fluid 
contaminants, as the membrane is the last barrier to the patients’ blood. Endotoxins (and 
other types of microbial contamination) are removed from dialysis fluid mainly by one of 
two methods: filtration and adsorption. Studies have shown that both methods of endotoxin 
removal occur during dialysis treatment (Osumi et al., 1995). Understanding endotoxin 
interactions with various membrane surfaces is imperative in order to orchestrate changes 
that will have a positive impact on endotoxin removal. The end goal of all endotoxin 
research is to limit patient exposure, in hopes of reducing the chance for pyrogenic 
reactions, inflammation, and shock. 
2.1 Membrane geometry 
Prior to synthetic membranes occupying the majority of the dialysis filter market, cellulosic 
membranes were the predominant choice for manufacturers. Cellulose was a material that 
could be modified to improve its biocompatibility; however its geometrical manipulation 
was limited due to the production process. As membrane materials progressed from 
cellulose-based to synthetic, numerous adjustments could be made to the physical 
characteristics of the membrane by relatively simple manufacturing process changes. 
One of the most direct methods to inhibit endotoxin is to change the material structure of 
the membrane itself, as the physical attributes of the membrane will perhaps have the 
greatest effect on endotoxin removal. Typically a thin-wall membrane is not as robust as a 
thick-wall membrane, in terms of endotoxin adsorption, since a thicker membrane can offer 
more surface area for the endotoxin to come into contact with. A thicker membrane provides 
a longer path for the endotoxin to maneuver through, before it reaches the blood circuit. An 
important characteristic of this path from outer membrane surface to inner membrane 
lumen is tortuosity, the curving path that the endotoxin must follow in order to reach the 
blood compartment of the fiber membrane (Osumi et al., 1995). As tortuosity is increased, 
the greater the chance the membrane has at prohibiting the passage of endotoxin. 
Membrane geometry changes can lead to differences in the adsorptive capacity for 
endotoxin (Vanholder & Pedrini, 2008; Vaslaki et al., 2000) and for bacteria (Waterhouse & 
Hall, 1995). 
Changes in membrane permeability are controlled to enhance convective transfer, which 
targets middle molecular removal of species such as β2Microglobulin and vitamin B12. As 
dialysis membranes are pushed for more convective removal ability, the opportunity for 
endotoxin trans-membrane flux increases due to the higher chance of back-filtration. Future 
membranes designed to address middle molecule removal by increasing internal filtration 
(Mineshima et al., 2009) will not improve on patient inflammation (Kerr et al., 2007) unless 
membrane geometry is modified to improve endotoxin removal.  
The effect of membrane thickness and permeability on endotoxin removal was studied by 
testing various membrane configurations, and by observing their ability to restrict 
contaminant flux. Synthetic membranes for testing were manufactured with specific 
geometries to observe their performance relative to a control. Fiber geometries tested 
included low flux, high flux, thin wall, thick wall, macrovoid, and a control. Characteristics 
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of each test membrane produced for this study are listed below in Table 1. The endotoxin 
challenge solution used was comprised of a 1:1 mixture of bacterial culture filtrates of 
Stenotrophomonas maltophilia (ATCC 13637) and Pseudomonas aeruginosa (ATCC 27853), 
both common water organisms. Cultures of each microorganism were ultra-sonicated to lyse 
the cells and release the endotoxin fragments, then filtered using a sequentially-decreasing 
process resulting in a final 0.2 μm filtration step.  
 
Fiber Type Fiber ID, μm Fiber Wall, μm 
Fiber Kuf, 
mL/hr*mmHg 
Material, Fiber 
type 
Control 185 35 200 
Polysulfone (PS), 
asymmetric 
Low Flux 181 39 48 PS, asymmetric 
High Flux 182 37 522 PS, asymmetric 
Thin Wall 187 24 231 PS, asymmetric 
Thick Wall 184 44 190 PS, asymmetric 
Macrovoid 212 33 130 PS, dual skin 
Table 1. Fiber membrane geometries  
Bacterial culture filtrates were used instead of purified LPS to produce challenge material 
that would closely resemble clinical experiences. Membranes were tested for their ability to 
restrict the passage of endotoxin across the membrane by either filtration or adsorption, by 
using a test setup (Figure 1) that focused on the diffusive and convective aspects of 
hemodialysis. The first setup focuses on diffusive testing, whereby the counter current flow 
mimics a typical hemodialysis treatment. The second setup in the test forces fluid to flow 
through the membrane, testing the filtration capacities of each fiber membrane. Initially, the 
test setup involved connecting the test dialyzer to a recirculating loop, where it could be 
connected to a peristaltic pump to control the flow of fluid on the blood loop. The dialysis 
fluid loop consisted of tubing that was connected to a reservoir, which allowed fluid to be 
recirculated through the dialysis fluid compartment, via another peristaltic pump. This 
reservoir held 1 liter of challenge solution, containing bacterial culture filtrate mixed into 
saline to produce an endotoxin concentration of 400 +/- 50 EU/mL. The blood loop  
 
 
 
Fig. 1. Endotoxin challenge test setup, showing the blood loop and dialysis fluid loop 
flowrates for both diffusive and convective testing. 
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peristaltic pump was set at 200 mL/min to recirculate the enclosed saline, while the dialysis 
fluid loop pump was set at 500 mL/min to recirculate the endotoxin challenge solution from 
the reservoir, through the dialyzer, and back. This test setup was maintained inside an 
incubator set at 37 C. Prior to starting the test, the dialyzer (both blood loop and dialysis 
fluid loop) were primed with sterile saline, to rinse out any residual endotoxin that may be 
contained within the test setup. Once the pumps were initiated, a timer was started and 
samples were taken from both the blood loop and dialysis fluid loop at the following times: 
0, 7, 15, and 60 minutes. Following the 60 minute sample, the test setup was changed 
according to Figure 1, so that dialysis fluid was forced across the membrane into the blood 
loop, and back into the challenge reservoir. Again, samples were taken following the start of 
the second half of the experiment at 67, 75, and 120 minutes. Samples were kept refrigerated 
at 4 C until ready to be analyzed for endotoxin content.  
Endotoxin activity was measured using a kinetic turbidimetric Limulus Amoebocyte Lysate 
(LAL) assay from Charles River Labs. Each sample was measured in duplicate, along with a 
positive control to verify recovery within the sample. Results from these tests are shown in 
Figure 2, with curves to represent both blood side and dialysis fluid side endotoxin 
concentrations. The data were able to show that only the control and thick wall membranes 
were able to contain the endotoxin in the blood side below < 0.1 EU/mL; all other 
membrane types allowed measurable amounts of endotoxin to cross into the enclosed blood 
loop circuit. Also, the results indicate that some membranes perform better at prohibiting    
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Fig. 2. Endotoxin challenge results for test simulations (all tests, n=3). a) Control membrane; 
b) Low and High Kuf membranes; c) Thin, Thick Wall membranes; d) Macrovoid 
membrane. 
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diffusive endotoxin flux than convective endotoxin flux, and vice versa. In particular, the 
high flux and thin wall membranes allowed the highest amounts of endotoxin into the blood 
compartment, as these membranes present the shortest tortuous path (thin wall) and the 
highest potential for back-diffusion along the membrane (high flux). These findings suggest 
that asymmetric, thick membranes are better suited at removing endotoxin from solution, as 
well as allowing endotoxin and other pyrogenic substances from crossing the membrane 
and contaminating a patient blood-flow.    
Not only is a thick fiber good at preventing endotoxin contamination to the patient, but the 
outer or inner membrane surface of the fiber membrane are imperative at preventing trans-
membrane endotoxin flux. Pore size distribution, or surface morphology, is a strictly 
controlled process in how to determine the flux of the dialyzer, and in allowing molecules of 
a certain size to either pass through the membrane surface, or be retained. Dialysis 
membrane pore sizes are not manufactured with endotoxin transfer in mind; however the 
pores play a critical role in regulating trans-membrane passage. Membrane thickness, 
structure, and surface morphology influence the membranes’ ability in preventing 
endotoxin transfer through geometrical means, mostly by way of filtration. However, 
chemical changes within the membrane can also add benefits towards increased endotoxin 
performance, with respect to removal by way of adsorption.      
2.2 Membrane surface changes 
Similar to how membrane geometry directly affects the endotoxin sieving ability, the surface 
properties of membranes will govern the adsorption capacity for endotoxin by providing a 
suitable surface for endotoxin and endotoxin fragments to adsorb by utilizing their 
amphiphilic nature. The hydrophobic lipid A moiety is typically attracted to hydrophobic 
surfaces, however the hydrophilic polysaccharide component will also allow for adsorption 
to hydrophilic surfaces (Takemoto et al., 2003). Recent studies have shown this to be the 
case, particularly for ultrafilters which remove endotoxin by way of adsorption through 
ionic and hydrophobic interactions (Vaslaki et al, 2000). When adjusting the polymer ratios 
of dialysis fiber membrane, chemical changes as well as physical changes can be produced. 
The overall geometry of the fiber can be manipulated by the polymer ratio – whether the 
fiber is based upon a sponge structure, whether the membrane possesses macrovoids, or 
whether the membrane exhibits one skin or two.  
Synthetic dialysis membranes from polysulfone are typically hydrophobic in nature, thus 
adding to their ability in being a good hemocompatible membrane for blood interaction. 
When manufacturing such membranes it is necessary to utilize a hydrophilic polymer that 
allows for the membrane to “wet”; to possess hydrophilic regions or properties. By simply 
adjusting the ratio of hydrophobic polymer (polysulfone) to hydrophilic polymer 
(polyvinylpyrrolidone or PVP), the membrane hydrophobicity composition can be changed 
significantly. A membrane that incorporates varying regions of hydrophobicity may be able 
to exploit the amphiphilic nature of endotoxin, resulting in numerous opportunities to 
remove it from dialysis fluid via adsorption (Maitz et al., 2009). Enhanced endotoxin 
removal has been shown feasible by increasing the surface polarity of the membrane 
(Rimmele et al, 2008). Polysulfone membranes typically exhibit a net negative surface 
charge, termed zeta potential, which may aid in their ability to remove endotoxin through 
adsorption (Mares et al, 2009; Shao et al., 2007). Similar behaviors are witnessed when 
endotoxin solutions are kept in glass containers; the glassware adsorbs a portion of the 
endotoxin, thus necessitating the glass to be cleaned or “depyrogenated.” 
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A special consideration to not overlook is where dialysis clinics practice reuse; numerous 
studies have investigated the effect of reprocessing agents on dialysis membrane 
performance and the resulting effect on endotoxin retention (Teehan et al., 2004; Sundaram 
et al., 1996). For those using bleach as a disinfectant and sterilizing agent, its use has to be 
taken into account as repeated exposure to membranes have been shown to increase solute 
clearance, as well as increase the net negative charge, thus increasing hydrophilicity (Shao et 
al., 2007).   
Polymer mixes were varied for test membranes, to study the endotoxin removal 
performance based upon chemical surface changes. Membranes, manufactured for this 
study, included those composed of high and low PVP content, a membrane consisting of a 
polymer mixture (polysulfone, PEG) and a membrane exposed to bleach – to determine how 
fiber surface differences affect the overall ability to remove endotoxin from solution. Also, 
membranes were tested using a fluorescent-labeled endotoxin to show the distribution of 
endotoxin within the membrane, modified from prior studies (Hayama et al., 2002). The 
experimental test setup was similar to that used to test fiber geometries – the test 
environment temperature, blood loop and dialysis fluid loop flow rates, endotoxin 
challenge concentration, and sample analysis method were all kept constant as described 
previously.  
An additional test was performed for these membranes, using a labeled endotoxin to identify 
where the endotoxin molecule is removed from solution within the fiber membrane. To 
accomplish this, miniature dialyzers were constructed of small polycarbonate housings and 
T’s to create a membrane dialyzer that could filter a smaller volume of fluorescent challenge 
solution, a mixture of Alexa Fluor 568 (Invitrogen, Carlsbad, CA) in saline to produce a 
concentration of 2,000 EU/mL. Membranes were challenged using a test setup similar to the 
diffusive setup used for the endotoxin challenge simulations, utilizing a challenge fluid flow 
on the dialysis fluid side of 5 mL/min, and a countercurrent fluid flow of saline on the blood 
side of 2 mL/min. Upon completion of the diffusive test, fibers were extracted from the 
miniature dialyzer housings and fixed into freezing media. A cryostat was used to slice the 
membrane samples into 10 um sections, which were then imaged using a microscope fit with a 
resorufin filter to observe the distribution of endotoxin on the membrane.  
Membrane permeability tests (Figure 3) were able to show how the bleached membrane, the 
high PVP content membrane, as well as the polymer mixture membrane, all allowed   
significant amounts of endotoxin to cross into the blood loop compartment. Fluorescent 
imaging revealed that for all membranes the majority of the endotoxin (highest intensity) 
was bound at either the inner or outer lumen of the fiber; also, differences could be seen in 
the distribution of endotoxin inside the bulk of the membrane, with some membranes 
showing high intensity, while others hardly could be imaged due to the low intensity of the 
endotoxin (Figure 4). 
These results indicate that chemical changes to the membrane can be manipulated in order 
to direct the preferential adsorption of endotoxin in a discreet region of the fiber, such as the 
outer lumen or inner lumen. These types of changes may be beneficial depending upon the 
intended use of the membrane, such as dialysis or ultrafiltration. Researchers have 
postulated that the region within the membrane where endotoxin is removed is important, 
as it has been shown to induce cytokine activation in blood within a dialyzer when bound 
adjacent to the lumen surface (Okamoto et al., 2004). These test results also provide insight 
into the nature of where and how endotoxin is bound or adsorbs to the membrane, 
furthering our understanding in how to remove it from solutions.  
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Fig. 3. Endotoxin challenge results for test simulations (all tests, n=3). a) Control membrane; 
b) Low, High PVP membranes; c) Copolymer, Bleach membranes; d) PES Sponge 
membrane. 
 
 
           
Fig. 4. Fiber membrane sections showing the distribution of fluorescent-labeled endotoxin 
(Alexa Fluor 568, imaged using a Resorufin filter). 
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2.3 Membrane material 
The type of membrane structure possible, which directly relates to the endotoxin removal 
mechanism (filtration, adsorption), is largely governed by the material used to produce the 
membrane. Polysulfone is currently the most common membrane material in the chronic 
dialysis market, but is only one of several choices available to patients and nephrologists. 
Dialysis membranes may also be produced from materials such as cellulose, poly methyl 
methacrylate (PMMA), polyester-polymer alloy (PEPA), polyethersulfone, polyamide, and 
cuprophane. Use of cuprophane membranes modified with vitamin E (Girndt et al., 2000), 
highlight the potential for modifications of specific membrane materials.  Significant research 
has been produced to show superior performance for endotoxin removal by synthetic 
membranes (Yamamoto & Kim, 1996; Nube & Grooteman, 2001); however, research has also 
exploited differences in the capacity for endotoxin between membranes of the same material, 
indicating that slight differences in the manufacturing and finishing processes may have a 
significant impact on the ultimate performance (Opatrny Jr. et al., 2006). On the contrary, 
studies have shown that in some instances it is difficult to show a clinical benefit when 
comparing differing membranes (Boudville et al., 2009; Urena et al., 1992).  
The effect of various fiber membrane materials on endotoxin retention was studied by 
testing polysulfone, cellulose triacetate, and polyethersulfone dialysis membranes using 
endotoxin permeability studies. An endotoxin challenge of 400 ± 50 EU/mL was created by 
spiking sterile saline with bacterial culture filtrates of a 1:1 mixture of P. aeruginosa (ATCC 
27853) and S. maltophilia (ATCC 13637). Simulation experiments were conducted to assess 
endotoxin transfer under both diffusive and convective conditions, with sterile saline used 
to model blood in the blood-side circuit. Flow rates used were similar to prior studies (QB = 
200 mL/min, QD = 500 mL/min) and the experimental temperature was kept constant at 37 
C. Samples were taken at times similar to prior studies, and were analyzed using a kinetic 
turbidimetric LAL assay with a detection limit of 0.1 EU/mL.    
The results from these studies (Figure 5) show sponge-structure polysulfone performed the 
best at prohibiting endotoxin to cross the membrane, under diffusive and convective 
hydraulic conditions. Cellulose triacetate and polyethersulfone both allowed endotoxin to 
cross into the inner lumen space of the membrane; it is unclear if these results are 
indications to limits of endotoxin removal regarding the fiber lumen (pore size) or lumen 
surface adsorption. Material choice will dictate what type of endotoxin removal will 
predominate – filtration or adsorption – as certain materials will produce specific structure 
geometries when undergoing the manufacturing process.  
Also, material choice will determine if a membrane is a good candidate for a particular 
coating or surface treatment to be applied; to aid in either creating a more biocompatible 
surface, or to enhance the endotoxin retentive properties.   
2.4 Membrane coatings 
Membrane coatings or surface treatments are not usually found on general use dialyzers; 
rather, they are used to add enhancements to dialyzers to better help a niche group of 
patients – whether the need is improved biocompatibility, better anticoagulation, or a 
reduction in circulating inflammatory cytokines. Surface treatments or coatings could be 
used to remove endotoxin; however, no coatings for dialyzer membranes (to date) have 
been produced to directly address endotoxin adsorption or removal. A coating which could 
produce a mixture of hydrophobic and hydrophilic regions would increase the adsorptive 
capacity of the membrane to retain circulating endotoxin – and at the same time may aid in 
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filtrative endotoxin removal. Coatings applied to the membrane post-production should be 
designed to not decrease/impede any solute clearance performance of the membrane, or 
inhibit membrane performance in any way. 
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Fig. 5. Endotoxin challenge results for test simulations (all tests, n=3). a) Control membrane 
(PS); b) Polysulfone, low-flux and high-flux; c) Cellulose, CTA and PEG coated; d) 
Polyethersulfone, low-flux and high-flux. 
Charcoal suspension has been tested as a potential adsorbent for diaysis, although it has 
been shown to induce platelet activation (Kramer et al., 2000). One significant area of 
research on endotoxin adsorption is for septic patients. Numerous techniques have been 
tested to remove circulating inflammatory cytokines from patient blood, as well as remove 
endotoxin. Polymyxin-B has been studied as an endotoxin binder, due to its affinity to the 
lipid A component and as it disrupts the permeability of cytoplasmic membranes of Gram 
negative bacteria (Uriu et al., 2002; Jaber & Pereira, 1997; Tani et al., 1998).  Polyethylenimine 
has been researched as a potential endotoxin adsorbent, and may be more compatible than 
other types of resins in similar applications (Mitzner et al., 1993). The most prevalent 
treatment is to use apheresis and hemoperfusion, removing specific targets by resins or 
coated fibers (Ronco et al., 2000; Szathmary et al., 2004; Yaroustovsky et al., 2009; Umgelter 
et al., 2008). Some of these endotoxin-specific adsorbents that have been proven effective 
may come with deleterious side effects (Steczko et al., 1999; Tani et al., 1998).  
Efficacy of a potential endotoxin-specific coating application was investigated by treating 
standard dialysis membranes with two specific polysaccharides (neutral and positive 
charged chitosan), a tri-block copolymer, and by using a bleach rinse. These modified 
membranes were tested for their endotoxin retention capacity by using the endotoxin 
simulation procedure described previously, with the same flow rates (QB = 200 mL/min, QD 
= 500 mL/min) and an endotoxin dialysis fluid challenge of 440 ± 55 EU/mL. However, the 
duration of the experiment was extended to 6 hours (3 hrs. diffusive, 3 hrs. convective) to 
observe if any plateau of endotoxin filtration or adsorption were to occur. Sampling from 
the blood and dialysis fluid circuits occurred at the following times (minutes): -5, 0, 7, 15, 30, 
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and every 30 minutes afterwards until 3 hours had transpired. Samples were analyzed for 
endotoxin activity using a kinetic turbidimetric LAL assay with a detection limit of 0.1 
EU/mL.  
Results obtained from the test dialyzers with membrane coatings are shown in Figure 5, 
showing the endotoxin profile curves for the full 6 hours of testing. Samples analyzed from 
the chitosan and +chitosan membranes exhibited inflated spike recovery samples, indicative 
of false positive readings. It is likely that polysaccharide leaching out of the coating and into 
the recirculating saline solution in the blood compartment compromised the integrity of the 
samples. It is likely that the actual endotoxin crossing into the blood compartment for the 
chitosan and +chitosan samples is lower, however the overall endotoxin reduction in the 
dialysis fluid compartment did not justify repeating the tests using a buffering agent to 
mask the effects of the polysaccharides. The findings suggest that while all of the 
investigative treatments did enhance the removal of endotoxin, some were more successful 
than others (chitosan coatings<control<bleach treated<polymer coating). 
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Fig. 5. Endotoxin challenge results for test simulations (all tests, n=3). a) Control membrane; 
b) Bleach treated membrane; c) Chitosan, +Chitosan coated membranes; d) Polymer coated 
membrane. 
Follow-up experiments were conducted to further observe the ability of each membrane 
coating at adsorption of endotoxin by exposing each test membrane to a semi-static 
adsorption environment. Fiber membranes were extracted from test dialyzers, placing 35 
cm2 of each fiber type into a series of 50 mL conical tubes. Each tube was filled with 50 mL 
of sterile saline, and then spiked with varying amounts of endotoxin resulting in a gradient 
of concentrations for each membrane type (1, 2.5, 5, 10, 20, and 50 EU/mL). These tubes 
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were then fixed to a rotor in a 37 C environment, which provided thorough mixing for the 
test duration of 72 hours. Samples were taken at set intervals, and analyzed immediately 
using the kinetic turbidimetric LAL assay with a detection limit of 0.01 EU/mL. Data 
gathered from these tests were used to generate adsorption isotherms for each membrane, 
shown in Figure 6. These plots indicate that the polymer coated membrane removed more 
endotoxin, and at a higher rate, than both the bleach treated and control membranes. For all 
three test membranes, adsorption rates for the 1 and 2.5 EU/mL concentrations reached a 
plateau at about 60 hours, although at 72 hours the 20 and 50 EU/mL concentrations were 
still showing measurable adsorption of endotoxin. The adsorption rates were calculated as 
follows: control – 0.15 ml/cm2*hr; bleach – 0.11 ml/cm2*hr; polymer – 0.30 mL/cm2*hr. The 
results from the polymer coated membrane are promising, given that the adsorption rate of 
endotoxin was twice that of the control. These findings suggest that endotoxin-specific 
coatings for dialysis or ultra filtration membranes are a theoretical possibility, and may aid 
in other aspects of membrane performance. 
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Fig. 6. Adsorption isotherm curves calculated for control, bleach treated, and polymer 
coated membranes. Curves were calculated from endotoxin challenge solutions of 1, 2.5, 5, 
10, 20, and 50 EU/mL. Correlation coefficients for the control, bleach treated, and polymer 
coated membranes were r2 = 0.991, r2 = 0.994, and r2 = 0.989, respectively. 
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3. Discussion 
Patient health, as it relates to hemodialysis treatment, is of the utmost importance as the 
mortality and morbidity of ESRD patients is typically high. A strong push recently has been 
to move to the use of ultrapure dialysate in clinics, as studies have shown correlations 
between improvements in markers of inflammation and the use of dialysis fluid meeting the 
criteria of <0.1 CFU/mL and <0.03 EU/mL (Lonnemann & Kock, 2002; Ledebo, 2007a; 
Schindler, 2009; Schiffl et al., 2002). As some studies have shown that typical endotoxin 
concentrations are higher in dialysis fluid than RO water entering the hemodialysis machine 
(von Sengbusch et al., 1993), the ultrapure criteria of the dialysis fluid needs to be created 
just prior to the patient receiving treatment.  One method to produce and ensure the 
production of ultrapure dialysis fluid is to place an ultrafilter in the hydraulic path between 
the patient and the dialysis machine, as this filter will have the greatest impact to the final 
dialysis fluid solution prior to entrance into the dialyzer (Oliver et al., 1992; Schindler et al., 
2004).  
Studies in the literature have revealed significant removal rates for ultrafilters in vitro, 
typically >99% for endotoxin (Oliver et al., 1992; Krautzig et al., 1996), with log reduction 
values >3 desirable (Tsuchida et al., 2009). Ultrafilters are commonly used in HDF, where 
two filters are typically used in series to guarantee sterile fluid production – manufacturers 
of ultrafilters state that sterility of substitution fluid is only guaranteed if the machine feed 
water falls within certain criteria (Penne et al., 2009). However, as ultrafilters are exposed to 
disinfection agents and cleaning cycles their efficacy in removing endotoxin is reduced. A 
desirable application would be a novel surface treatment or coating that would enhance 
endotoxin removal, while able to resist efficiency loss induced by age and chemical 
exposure. Durable membranes have been studied, with some researchers looking at ceramic 
or alumina membranes. As these membranes do perform well in retaining endotoxin, their 
expense in manufacturing seems to limit their application, as well as some membranes have 
been shown to leach aluminum when cleaned with NaOH (Bender et al., 2000).    
The goal of endotoxin removal is ultimately to reduce patient inflammation, as 
contaminated dialysate has been linked to the systemic micro-inflammatory state observed 
in many hemodialysis patients (Ouseph et al., 2007). Other studies have reported links 
between inflammation and cardiovascular disease (CVD) in hemodialysis patients (Merino 
et al., 2008; Wang et al., 2011; Kerr et al., 2007), while some have shown association between 
inflammation and nutritional status (Raj et al., 2009), implicating the breadth of influence 
caused by repeated endotoxin exposure. As more ESRD patients are treated with high-flux 
dialysis membranes, the opportunity increases for bacterial contaminants in dialysis fluid to 
cross the membrane into the blood and activate numerous cell types, releasing pro-
inflammatory cytokines which heighten the inflammatory condition  (Vanholder et al., 1992; 
Almeida et al., 2006). This is also the case in the acute market, as membranes with increased 
permeabilities are being used in ARF for their higher clearances of cytokines (Haase et al., 
2007; Vanholder et al., 2000); these patients will have higher risks for endotoxin 
contamination, based upon the membrane flux.  
Aside from removal, advances in the detection of endotoxin and other pyrogenic substances 
at low concentrations would further propel endotoxin research forward by providing 
researchers tools to better distinguish bacterial contaminant changes, or by making highly 
sensitive endotoxin detection available to clinics to provide advanced microbiological 
observation of their water systems. Specific research in this field has focused on the efficacy 
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of utilizing photometry to detect and measure endotoxin in patient plasma samples 
(Nakazawa et al., 2010), which would have direct impact on research clinics and for septic 
patients. PCR techniques have also been utilized for their application to dialysis research, by 
analyzing total flora in dialysis water via the 16s rDNA. As this technique guarantees a high 
degree of detection, it does not specify whether bacteria or live or dead, or what species are 
prevalent within the sample (Nystrand, 2006).      
4. Future work 
Studies involving endotoxin in hemodialysis have been going on for quite some time – 
covering how to prevent and remove biofilm from water distribution systems, how 
endotoxin interacts with the body, and how to increase removal efficiencies. Going forward, 
future work may involve identifying new bacterial contaminants that cause adverse patient 
reactions, but may not be identified by the LAL assay (Glorieux et al., 2009). There are a 
number of smaller bacterial components released during cell lysis, with bacterial DNA 
fragments recently receiving considerable attention in research studies (Handelman et al., 
2009; Schindler et al., 2004). Some of these studies have shown a correlation between bDNA 
fragments present in patient blood, and higher levels of CRP and IL-6 (Bossola et al., 2009). 
Current limitations in endotoxin quantitative methodology, which influence how bacterial 
contaminant results and target values are interpreted (Ledebo, 2007b) will hopefully be 
improved upon and expanded to cover additional areas of focus in ESRD treatment.  
The future of any therapy used to treat patients with ESRD needs to focus on the associated 
mortality and morbidity influencing factors. Whether ESRD therapy will focus on smaller, 
wearable devices (Gura et al., 2008; Ronco & Fecondini, 2007), strive for increases in home 
treatment (Moran, 2009), or devices utilizing living cells (Humes et al., 2006), the effect of 
endotoxin must be taken into account for each application – and to address the specific 
actions necessary to remove endotoxin thus ensuring patient safety. Future progress in 
endotoxin research will hopefully alleviate inflammation-related complications, and 
improve patient outcomes for all aspects of ESRD.  
5. Conclusion 
In conclusion, endotoxin contamination of fluid for dialysis therapy is an important aspect 
of patient safety and well-being. Regardless of the microbiological quality of the water 
coming into the hemodialysis machine, the dialysis membrane is the final barrier between 
potentially contaminated dialysis fluid, and the blood of the patient. We have examined 
how manipulation of specific fiber membrane parameters (geometric properties, materials, 
coatings, chemical modifications) can be utilized to improve the endotoxin retentive 
properties to limit trans-membrane flux, whether they contribute to adsorptive 
improvements, sieving improvements, or both. Membrane structure, surface chemistry, 
material, and surface coatings all have an impact on how endotoxin is filtered and adsorbed 
from solution. In addition to better understanding endotoxin-membrane interactions, 
studies of endotoxin removal by membrane modifications will result in better approaches to 
manufacture dialysis membranes that remove endotoxin from solution quickly and with 
improved efficiency. 
As future hemodialysis membranes are designed to further improve upon convective 
removal of larger middle molecular solutes such as B2M, the opportunity for pyrogenic 
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materials to enter the blood stream via back filtration becomes greater. An improved 
comprehension of how endotoxin is removed using a fiber membrane can lead to new 
improvements and future product designs, by streamlining concepts from development to 
production.   
6. Acknowledgment 
The authors would like to express their gratitude to Mr. Doug Olmstead and Mr. Marion 
Andersen for their support and guidance with the LAL analysis, and to Dr. David Britt and 
Dr. Ben Madsen for their assistance and work with the fluorescence assay.  
7. References 
Almeida, W., Maciel, T., Di Marco, G., Casarini, D., Campos, A., Schor, N. (2006). 
Escherichia coli lipopolysaccharide inhibits renin activity in human mesangial cells. 
Kidney International, Vol.69, No.1, pp.974-980. 
Bailat, S., Heumann, D., Roy, D., Baumgartner, J., Rietschel, E., Glauser, M., Padova, F. 
(1997). Similarities and disparities between core-specific and O-side-chain-specific 
antilipopolysaccharide monoclonal antibodies in models of endotoxemia and 
bacteremia in mice. Infection Immunity, Vol.65, No.2, pp.811-814. 
Bender, H., Pflanzel, A., Saunders, N., Czermak, P., Catapano, G., Vienken, J. (2000). 
Membranes for endotoxin removal from dialysate: Considerations on feasibility of 
commercial ceramic membranes. Artificial Organs, Vol.24, No.10, pp.826-838. 
Bland, L., Oliver, J., Arduino, M., Oettinger, C., McAllister, S., Favero, M. (1994). Potency of 
endotoxin from bicarbonate dialysate compared with endotoxins from Escherichia 
coli and Shigella flexneri. JASN, Vol.5, No.1, pp.1634-1637. 
Bossola, M., Sanguinetti, M., Scribano, D., Zuppi, C., Giungi, S., Luciani, G., Torelli, R., 
Posteraro, B., Fadda, G., Tazza, L. (2009). Circulating bacterial-derived DNA 
fragments and markers of inflammation in chronic hemodialysis patients. Clinical 
JASN, Vol.4, No.1, pp.379-385. 
Boudville, N., Horner, M., McEwan, E., Lim, W., Mudge, D., Markus, H. (2009). Effect of FX 
dialysers on systemic inflammation and quality of life in chronic haemodialysis 
patients. Blood Purification, Vol.27, No.1, pp.187-193. 
Canaud, B., Bosc, J., Leray, H., Stec, F. (2000). Microbiological purity of dialysate for on-line 
substitution fluid preparation. Nephrology Dialysis Transplantation, Vol.15, Suppl.2, 
pp.21-30. 
Girndt, M., Lengler, S., Kaul, H., Sester, U., Sester, M., Kohler, H. (2000). Prospective 
crossover trial of the influence of vitamin E-coated dialyzer membranes on T-cell 
activation and cytokine induction. American J Kidney Diseases, Vol.35, No.1, pp.95-
104. 
Glorieux, G., Schepers, E., Schindler, R., Lemke, H., Verbeke, F., Dhondt, A., Lameire, N., 
Vanholder, R. (2009). A novel bio-assay increases the detection yield of 
microbiological impurity of dialysis fluid, in comparison to the LAL-test. 
Nephrology Dialysis Transplantation, Vol.24, No.1, pp.548-554. 
Gomila, M., Gasco, J., Gil, J., Bernabeu, R., Inigo, V., Lalucat, J. (2006). A molecular microbial 
ecology approach to studying hemodialysis water and fluid. Kidney International, 
Vol.70, No.1, pp.1567-1576.  
www.intechopen.com
 
Progress in Hemodialysis – From Emergent Biotechnology to Clinical Practice 
 
212 
Gorbet, M., Sefton, M. (2005). Endotoxin: the uninvited guest. Biomaterials, Vol.26, No.1, 
(month/year of edition), pp.6811-6817. 
Gunn, J. (2001). Bacterial modification of LPS and resistance to antimicrobial peptides. J 
Endotoxin Res, Vol.7, No.1, pp.57-62. 
Gura, V., Ronco, C., Davenport, A. (2008). The wearable artificial kidney, why and how: 
from holy grail to reality. Seminars in Dialysis, Vol.22, No.1, pp. 13-17. 
Haase, M., Bellomo, R., Baldwin, I., Haase-Fielitz, A., Fealy, N., Davenport, P., Morgera, S., 
Goehl, H., Storr, M., Boyce, N., Neumayer, H. (2007). Hemodialysis membrane with 
a high-molecular-weight cutoff and cytokine levels in sepsis complicated by acute 
renal failure: A phase 1 randomized trial. American J Kidney Diseases, Vol.50, No.1, 
pp.296-304. 
Haeffner-Cavaillon, N., Carreno, M., Aussel, L., Caroff, M. (1998). Molecular aspects of 
endotoxins relevant to their biological functions. Nephrology Dialysis Transplantation, 
Vol.14, No.1, pp.853-860. 
Handelman, G., Megdan, P., Handelman, S. (2009). Bacterial DNA in water and dialysate: 
Detection and significance for patient outcomes. Blood Purification, Vol.27, No.1, 
pp.81-85. 
Hayama, M., Miyasaka, T., Mochizuki, S., Asahara, H., Tsujioka, K., Kohori, F., Sakai, K., 
Jinbo, Y., Yoshida, M. (2002). Visualization of distribution of endotoxin trapped in 
an endotoxin-blocking filtration membrane. J Membrane Science, Vol.210, No.1, 
pp.45-53. 
Hoenich, Nicholas. (2007). The extracorporeal circuit: Materials, problems, and solutions. 
Hemodialysis International, Vol.11, No.1, pp.s26-s31. 
Humes, H., Fissell, W., Tiranathanagul, K. (2006). The future of hemodialysis membranes. 
Kidney International, Vol.69, No.1, pp.1115-1119. 
Jaber, B., Pereira, B. (1997). Extracorporeal adsorbent-based strategies in sepsis. American J 
Kidney Diseases, Vol.30, No.5, Suppl.4, pp.s44-s56. 
Kanagasundaram, N., Moore, I., Hoenich, N. (2009). Biofilm in bicarbonate-based 
replacement fluid circuits in CVVH. Kidney International, Vol.76, No.1, p.682. 
Kerr, P., Sutherland, W., de Jong, S., Vaithalingham, I., Williams, S., Walker, R. (2007). The 
impact of standard high-flux polysulfone versus novel high-flux polysulfone 
dialysis membranes on inflammatory markers : A randomized, single-blinded, 
controlled clinical trial. American J Kidney Diseases, Vol.49, No.1, pp.533-539. 
Khan, R., Badr, K. (1999). Endotoxin and renal function: Perspectives to the understanding 
of septic acute renal failure and toxic shock. Nephrology Dialysis Transplantation, 
Vol.14, No.1, pp.814-818. 
Kramer, L., Gendo, A., Madl, C., Ferrara, I., Funk, G., Schenk, P., Sunder-Plassmann, G., 
Horl, W. (2000). Biocompatibility of a cuprophane charcoal-based detoxification 
device in cirrhotic patients with hepatic encephalopathy. American J Kidney Diseases, 
Vol.36, No.6, pp.1193-1200. 
Krautzig, S., Lonnemann, G., Shaldon, S., Koch, K. (1996). Bacterial challenge of NISSHO 
ultrafilter ETF 609: Results of in vitro testing. Artificial Organs, Vol.20, No.7, pp.798-
800. 
Krieter, D., Lemke, H., Wanner, C. (2008). A new synthetic dialyzer with advanced 
permselectivity for enhanced low-molecular weight protein removal. Artificial 
Organs, Vol.32, No.7, pp.547-554. 
www.intechopen.com
 
Dialysis Membrane Manipulation for Endotoxin Removal 
 
213 
Ledebo, Ingrid. (2002). On-line preparation of solutions for dialysis: practical aspects versus 
safety and regulations. JASN, Vol.13, No.1, pp.78-83. 
Ledebo, Ingrid. (2007a). Clinical benefits of ultrapure dialysis fluid for hemodialysis. 
Hemodialysis International, Vol.11, No.1, pp.s12-s17. 
Ledebo, Ingrid. (2007b). Ultrapure dialysis fluid – how pure is it and do we need it? 
Nephrology Dialysis Transplantation, Vol.22, No.1, pp.20-23. 
Lonnemann, Gerhard. (2000). Should ultra-pure dialysate be mandatory? Nephrology Dialysis 
Transplantation, Vol.15, Suppl.1, pp.55-59. 
Lonnemann, G., Sereni, L., Lemke, H., Tetta, C. (2001). Pyrogen retention by highly 
permeable synthetic membranes during in vitro dialysis. Artificial Organs, Vol.25, 
No.12, pp.951-960. 
Lonnemann, G., Kock, K. (2002). Β2-Microglobulin amyloidosis: Effects of ultrapure 
dialysate and type of dialyzer membrane. JASN, Vol.13, No.1, pp.s72-s77. 
Maitz, M., Teichmann, J., Sperling, C., Werner, C. (2008). Surface endotoxin contamination 
and hemocompatibility evaluation of materials. J Biomedical Materials Research Part 
B, Vol.90B, No.1, pp.18-25. 
Mares, J., Thongboonkerd, V., Tuma, Z., Moravec, J., Matejovic, M. (2009). Specific 
adsorption of some complement activation proteins to polysulfone dialysis 
membranes during hemodialysis. Kidney International, Vol.76, No.1, pp.404-413. 
Merino, A., Nogueras, S., Garcia-Maceira, T., Rodriguez, M., Martin-Malo, A., Ramirez, R., 
Carracedo, J., Aljama, P. (2008). Bacterial DNA and endothelial damage in 
haemodialysis patients. Nephrology Dialysis Transplantation, Vol.23, No.1, pp.3635-
3642. 
Mineshima, M., Ishimori, I., Sakiyama, R. (2009). Validity of internal filtration-enhanced 
hemodialysis as a new hemodiafiltration therapy. Blood Purification, Vol.27, No.1, 
pp.33-37. 
Mitzner, S., Schneidewind, J., Falkenhagen, D., Loth, F., Klinkmann, H. (1993). 
Extracorporeal endotoxin removal by immobilized polyethylenimine. Artificial 
Organs, Vol.17, No.9, pp.775-781. 
Moran, John. (2009). Technical advances in home dialysis. Advances in Chronic Kidney Disease, 
Vol.16, No.3, pp.215-220. 
Nakazawa, R., Motohashi, K., Azuma, N., Obata, T. (2010). Effectiveness of endotoxin 
scattering photometry (ESP) for determining endotoxin levels of dialysis fluid for 
haemodialysis. ?,  
Nube, M., Grooteman, M. (2001). Impact of contaminated dialysate on long-term 
haemodialysis-related complications: Is it really that important? Nephrology Dialysis 
Transplantation, Vol.16, No.1, pp.1986-1991. 
Nystrand, Rolf. (2006). Modern microbiological techniques and their use in dialysis fluid 
systems: What are the benefits? Kidney International, Vol.70, No.1, pp.1539-1540. 
Ofsthun, N., Leypoldt, J. (1995). Ultrafiltration and backfiltration during hemodialysis. 
Artificial Organs, Vol.19, No.11, pp.1143-1161. 
Oliver, J., Bland, L., Oettinger, C., Arduino, M., Garrard, M., Pegues, D., McAllister, S., 
Moone, T., Aguero, S., Favero, M. (1992). Bacteria and endotoxin removal from 
bicarbonate dialysis fluids for use in conventional, high-efficiency, and high-flux 
hemodialysis. Artificial Organs, Vol.16, No.2, pp.141-145. 
www.intechopen.com
 
Progress in Hemodialysis – From Emergent Biotechnology to Clinical Practice 
 
214 
Opatrny Jr., K., Krouzecky, A., Polanska, K., Mares, J., Tomsu, M., Bowry, S., Vienken, J. 
(2006). Does an alteration of dialyzer design and geometry affect biocompatibility 
parameters? Hemodialysis International, Vol.10, No.1, pp.201-208. 
Osumi, M., Yamada, N., Toya, M. (1996). Bacterial retention mechanisms of membrane 
filters. PDA J Pharma Sci & Tech, Vol.50, No.1, pp.30-34. 
Qureshi, N., Kutuzova, G., Takayama, K., Rice, P., Golenbock, D. (1999). Structure of lipid A 
and cell activation. J Endotoxin Res, Vol.5, No.3, pp.147-150. 
Ouseph, R., Jones, S., Dhananjaya, N., Ward, R. (2007). Use of ultrafiltered dialysate is 
associated with improvements in haemodialysis-associated morbidity in patients 
treated with reused dialysers. Nephrology Dialysis Transplantation, Vol.22, No.1, 
pp.2269-2275. 
Penne, E., Visser, L., van den Dorpel, M., van der Weerd, N., Mazairac, A., van jaarsveld, B., 
Koopman, M., Vos, P., Feith, G., Hovinga, T., van hamersvelt, H., Wauters, I., Bots, 
M., Nube, M., ter Wee, P., Blankestijn, P., Grooteman, M. (2009). Microbiological 
quality and quality control of purified water and ultrapure dialysis fluids for online 
hemodiafiltration in routine clinical practice. Kidney Internatinal, Vol.76, No.1, 
pp.665-672. 
Perez-Garcia, R., Rodriguez-Benitez, P. (2000). Why and how to monitor bacterial 
contamination of dialysate? Nephrology Dialysis Transplantation, Vol.15, No.1, 
pp.760-764. 
Raetz, C. (1991). Gram negative endotoxin: an extraordinary lipid with profound effets on 
eukaryotic signal transduction. FASEB Journal, Vol.5, No.1, pp. 2652-2660. 
Raj, D., Carrero, J., Shah, V., Qureshi, A., Barany, P., Heimburger, O., Lindholm, B., 
Ferguson, J., Moseley, P., Stenvinkel, P. (2009). Soluble CD14 levels, interleukin 6, 
and mortality among prevalent hemodialysis patients. American J Kidney Diseases, 
Vol.54, No.1, pp.1072-1080. 
Rietschel, E., Kirikae, T., Schade, F., Mamat, U., Schmidt, G., Loppnow, H., Ulmer, A., 
Zahringer, U., Seydel, U., Padova, F.,Schreier, M., Brade, H. (1994). Bacterial 
endotoxin: molecular relationships of structure to activity and function. FASEB 
Journal, Vol.8, No.1, pp. 217-225. 
Rimmele, T., Assadi, A., Cattenoz, M., Desebbe, O., Lambert, C., Boselli, E., Goudable, J., 
Etienne, J., Chassard, D., Bricca, G., Allaouchiche, B. (2009). High-volume 
haemofiltration with a new haemofiltration membrane having enhanced 
adsorption properties in septic pigs. Nephrology Dialysis Transplantation, Vol.24, 
No.1, pp.421-427. 
Ronco, C., Brendolan, A., Dan, M., Piccinni, P., Bellomo, R., De Nitti, C., Inguaggiato, P., 
Tetta, C. (2000). Adsorption in sepsis. Kidney International, Vol.58, Suppl.76, pp.148-
155. 
Ronco, C., Fecondini, L. (2007). The Vicenza wearable artificial kidney for peritoneal dialysis 
(ViWAK PD). Blood Purification, Vol.25, No.1, pp.383-388. 
Sakamoto, Y., Mashiko, K., Obata, T., Yokota, H. (2010). Effectiveness of endotoxin 
scattering photometry for determining the efficacy of polymyxin B-immobilized 
fiber treatment in septic shock: Report of a case. J Nippon Medical School, Vol.77, 
No.2, pp.119-122. 
www.intechopen.com
 
Dialysis Membrane Manipulation for Endotoxin Removal 
 
215 
Schiffl, H., Lang, S., Fischer, R. (2002). Ultrapure dialysis fluid slows loss of residual renal 
function in new dialysis patients. Nephrology Dialysis Transplantation, Vol.17, No.1, 
pp.1814-1818. 
Schiffl, Helmut (2011). High-flux dialyzers, backfiltration, and dialysis fluid quality. 
Seminars in Dialysis, Vol.24, No.1, pp.1-4. 
Schindler, R., Beck, W., Deppisch, R., Aussieker, M., Wilde, A., Gohl, H., Frei, U. (2004). 
Short bacterial DNA fragments: Detection in dialysate and induction of cytokines. 
JASN, Vol.15, No.1, pp.3207-3214. 
Schindler, Ralf. (2009). Clinical effect of purification of dialysis fluids, evidence and 
experience. Blood Purification, Vol.27, Supp.1, pp.20-22. 
Shao, J., Wolff, S., Zydney, A. (2007). In vitro comparison of peracetic acid and bleach 
cleaning of polysulfone hemodialysis membranes. Artificial Organs, Vol.31, No.6, 
pp.452-460. 
von Sengbusch, G., Bowry, S., Vienken, J. (1993). Focusing on membranes. Artificial Organs, 
Vol.17, No.4, pp.244-253.  
Smeets, E., Kooman, J., vander Sande, F., Stobberingh, E., Frederik, P., Claessens, P., Grave, 
W., Schot, A., Leunissen, K. (2003). Kidney International, Vol.63, No.1, pp.1574-1576. 
Steczko, J., Ash, S., Blake, D., Carr, D., Bosley, R. (1999). Cytokines and endotoxin removal 
by sorbents and its application in push-pull sorbent-based pheresis: The biologic-
DTPF system. Artificial Organs, Vol.23, No.4, pp.310-318. 
Sundaram, S., Barrett, T., Meyer, K., Perrella, C., Neto, M., King, A., Pereira, B. (1996). 
Transmembrane passage of cytokine-inducing bacterial products across new and 
reprocessed polysulfone dialyzers. JASN, Vol.7, No.1, pp.2183-2191. 
Szathmary, S., Hegyi, E., Amoureux, M-C., Rajapakse, N., Chicorka, L., Szalai, G., Reszegi, 
K., Derbyshire, Z., Paluh, J., Dodson, B., Grandics, P. (2004). Characterization of the 
DialguardTM device for endotoxin removal in hemodialysis. Blood Purification, 
Vol.22, No.1, pp.409-415. 
Takemoto, Y., Nakatani, T., Sugimura, K., Yoshimura, R., Tsuchida, K. (2003). Endotoxin 
adsorption of various dialysis membranes: In vitro study. Artificial Organs, Vol.27, 
No.12, pp.1134-1142. 
Tani, T., Hanasawa, K., Endo, Y., Yoshioka, T., Kodama, M., Kaneko, M., Uchiyama, Y., 
Akizawa, T., Takahasi, K., Sugai, K. (1998). Theapeutic apheresis for septic patients 
with organ dysfunction: Hemoperfusion using a polymyxin B immobilized column. 
Artificial Organs, Vol.22, No.12, pp.1038-1044. 
Teehan, G., Guo, D., Perianayagam, M., Galakrishnan, V., Pereira, B., Jaber, B. (2004). 
Reprocessed (high-flux) Polyflux® dialyzers resist trans-membrane endotoxin 
passage and attenuate inflammatory markers. Blood Purification, Vol.22, No.1, 
pp.329-337. 
Tsuchida, K., Nakatani, T., Sugimura, K., Yoshimura, R., Matsuyama, M., Takemoto, Y. 
(2004). Biological reactions resulting from endotoxin adsorbed on dialysis 
membrane: An in vitro study. Artificial Organs, Vol.28, No.2, pp. 231-234, ISSN. 
Tsuchida, K., Nakamura, M., Yoshikawa, K., Minakuchi, J., Takesawa, S. (2009). Current 
situation of endotoxin retentive filter. Blood Purification, Vol.27, Suppl.1, pp.28-35. 
Umgelter, A., Reindl, W., Lutz, J., Kreymann, B., Ronco, C., Huber, W., Frank, H., Schmid, 
R., Heemann, U. (2008). Treatment of septic patients with an arginine-based 
www.intechopen.com
 
Progress in Hemodialysis – From Emergent Biotechnology to Clinical Practice 
 
216 
endotoxin adsorber column improves hemodynamics and reduces oxidative stress: 
results of a feasibility study. Blood Purificaiton, Vol.26, No.1, pp.333-339. 
Urena, P., Herbelin, A., Zingraff, J., Lair, M., Man, N., Descamps-Latscha, B., Drueke, T. 
(1992). Permeability of cellulosic and non-cellulosic membranes to endotoxin 
subunits and cytokine production during in-vitro haemodialysis. Nephrology 
Dialysis Transplantation, Vol.7, No.1, pp.16-28. 
Uriu, K., Osajima, A., Hiroshige, K., Watanabe, H., Aibara, K., Inada, Y., Segawa, K., Anai, 
H., Takagi, I., Ito, A., Kamochi, M., Kaizu, K. (2002). Endotoxin removal by direct 
hemoperfusion with an adsorbent column using polymyxin B-immobilized fiber 
ameliorates systemic circulatory disturbance in patients with septic shock. American 
J Kidney Diseases, Vol.39, No.5, pp.937-947. 
Valvano, Miguel. (1992). Pathogenicity and molecular genetics of O-specific side-chain 
lipopolysaccharides of Escherichia coli. Canadian J Microbiology, Vol.38, No.1, 
pp.711-719. 
Vanholder, R., Van Haecke, E., Veys, N., Ringoir, S. (1992). Endotoxin transfer through 
dialysis membranes: Small- versus large-pore membranes. Nephrology Dialysis 
Transplantation, Vol.7, No.1, pp.333-339. 
Vanholder, R., De Vriese, A., Lameire, N. (2000). The role of dialyzer biocompatibility in 
acute renal failure. Blood Purification, Vol.18, No.1, pp.1-12. 
Vanholder, R., Pedrini, L. (2008). All high-flux membranes are equal but some high-flux 
membranes are less equal than others. Nephrology Dialysis Transplantation, Vol.23, 
No.1, pp.1481-1483. 
Vaslaki, L., Karatson, A., Voros, P., Major, L., Petho, F., Ladanyi, E., Weber, C., Mitteregger, 
R., Falkenhagen, D. (2000). Can sterile and pyrogen-free on-line substitution fluid 
be routinely delivered? A multicentric study on the microbiological safety of on-
line haemodiafiltration. Nephrology Dialysis Transplantation, Vol.15, Suppl.1, pp.74-
78. 
Wang, A., Sanderson, J. (2011). Current perspectives on diagnosis of heart failure in long-
term dialysis patients. American J Kidney Disease, Vol. 57, No.2, pp.308-319. 
Waterhouse, S., Hall, G. (1995). The validation of sterilising grade microfiltration 
membranes with Pseudomonas diminuta. J Membrane Science, Vol.104, No.1, pp.1-9. 
Weber, V., Linsbetrge, I., Rossmanith, E., Weber, C., Falkenhagen, D. (2004). Pyrogen 
transfer across high and low-flux hemodialysis membranes. Artificial Organs, 
Vol.28, No.2, pp.210-217. 
Weber, V., Linsberger, I., Falkenhagen, D. (2009). Negligible transfer of endotoxins across 
high-flux haemodialysis membranes designed for convective therapies. Nephrology 
Dialysis Transplantation Plus, Vol.2, Suppl.2, ii1901-. 
Yamamoto, C., Kim, S. (1996). Endotoxin rejection by ultrafiltration through high-flux, 
hollow fiber filters. J Biomedical Materials Research, Vol.32, No.1, pp.467-471. 
Yaroustovsky, M., Abramyan, M., Popok, Z., Nazarova, E., Stupchenko, O., Popov, D., 
Plushch, M., Samsonova, N. (2009). Preliminary report regarding the use of 
selective sorbents in complex cardiac surgery patients with extensive sepsis and 
prolonged intensive care stay. Blood Purification, Vol.28, No.1, pp.227-233. 
www.intechopen.com
Progress in Hemodialysis - From Emergent Biotechnology to
Clinical Practice
Edited by Prof. Angelo Carpi
ISBN 978-953-307-377-4
Hard cover, 444 pages
Publisher InTech
Published online 07, November, 2011
Published in print edition November, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Hemodialysis (HD) represents the first successful long-term substitutive therapy with an artificial organ for
severe failure of a vital organ. Because HD was started many decades ago, a book on HD may not appear to
be up-to-date. Indeed, HD covers many basic and clinical aspects and this book reflects the rapid expansion of
new and controversial aspects either in the biotechnological or in the clinical field. This book revises new
technologies and therapeutic options to improve dialysis treatment of uremic patients. This book consists of
three parts: modeling, methods and technique, prognosis and complications.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Michael Henrie, Cheryl Ford, Eric Stroup and Chih-Hu Ho (2011). Dialysis Membrane Manipulation for
Endotoxin Removal, Progress in Hemodialysis - From Emergent Biotechnology to Clinical Practice, Prof.
Angelo Carpi (Ed.), ISBN: 978-953-307-377-4, InTech, Available from:
http://www.intechopen.com/books/progress-in-hemodialysis-from-emergent-biotechnology-to-clinical-
practice/dialysis-membrane-manipulation-for-endotoxin-removal
© 2011 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
